Question 1

What is MOHAP and why is it important for medical device manufacturers?

Accepted Answer

The Ministry of Health and Prevention (MOHAP) is the UAE's federal regulatory authority responsible for medical device regulation, registration, and market surveillance. MOHAP enforces the GCC (Gulf Cooperation Council) medical device regulations, which have been harmonized across GCC member states (UAE, Saudi Arabia, Bahrain, Kuwait, Oman, Qatar). All medical devices marketed in the UAE require Medical Device Marketing Authorization (MDMA) from MOHAP, and foreign manufacturers must designate a local agent in the UAE. The UAE also has specialized free zones (e.g., Dubai Healthcare City) with specific regulations.

Question 2

What is the GCC Medical Device Regulations and how does it affect the UAE?

Accepted Answer

The GCC Medical Device Regulations (GCC-DR), established through the GCC Standardization Organization (GSO) and enforced by the Saudi FDA's Gulf Committee for Medical Devices, aim to harmonize medical device regulations across the Gulf Cooperation Council member states. Key Features for UAE: Aligned classification system (Class A-D based on risk), common conformity assessment procedures, recognition of international standards and certifications, harmonized technical documentation requirements, mutual recognition provisions (limited). UAE Implementation: MOHAP enforces GCC-DR through MDMA process, UAE-specific local agent and registration requirements still apply, free zones may have additional requirements. The GCC-DR facilitates regional market access while individual countries maintain sovereign registration systems.

Question 3

What is MDMA and what are the registration requirements in the UAE?

Accepted Answer

Medical Device Marketing Authorization (MDMA) is the approval required from MOHAP to market medical devices in the UAE. Key Requirements: Device Classification (Class A-D per GCC-DR), UAE Local Agent designation (mandatory for foreign manufacturers), Quality Management System certificate (ISO 13485 or equivalent), Conformity Certificate (CE marking, FDA clearance, or other recognized certifications preferred), Technical Documentation (device description, intended use, labeling, instructions for use), Free Sale Certificate (from country of origin). Registration Process: Submit application via MOHAP portal, technical review by MOHAP (timeline varies by class: Class A ~1-2 months, Class B-C ~3-4 months, Class D ~6+ months), upon approval receive MDMA certificate. MDMA must be renewed periodically (typically every 3-5 years).

Question 4

What is a UAE Local Agent and what are their responsibilities?

Accepted Answer

A UAE Local Agent (also called Authorized Representative or Local Distributor) is a person or company established in the UAE designated by a foreign manufacturer to represent them with MOHAP and handle device distribution. Requirements: Must be domiciled in the UAE with valid trade license, registered with MOHAP as a medical device agent, Responsibilities: Submit and maintain MDMA applications with MOHAP, serve as liaison between manufacturer and MOHAP, maintain technical documentation, certificates, and product information, handle post-market surveillance and adverse event reporting, coordinate recalls and corrective actions, ensure compliance with labeling and Arabic language requirements. A UAE Local Agent is mandatory for all foreign manufacturers (including EU and US companies) marketing devices in the UAE.

Question 5

How does the UAE medical device classification system work?

Accepted Answer

The UAE follows the GCC-DR classification system, which is risk-based and aligned with international standards: Class A: Low risk (e.g., non-invasive devices, general examination devices), Class B: Medium risk (e.g., short-term invasive, active therapeutic devices), Class C: Medium-high risk (e.g., long-term invasive, devices with biological substances), Class D: High risk (e.g., implantable, life-supporting, drug-device combinations). Classification is determined by factors including: invasiveness, duration of contact, whether device is active, interaction with medicines or body tissues, intended purpose. Higher class devices require more extensive technical documentation, third-party conformity assessment, and longer MOHAP review times.

Question 6

What are the Dubai Free Zones and how do they affect medical device regulation?

Accepted Answer

Dubai has established several healthcare-focused free zones with specific regulatory frameworks: Dubai Healthcare City (DHCC): Special development zone with Dubai Health Authority (DHA) oversight, streamlined registration for healthcare facilities within the zone, specific requirements for devices used in DHCC facilities. Key Considerations: Devices registered in free zones may have limitations on distribution outside the zone, MOHAP registration still required for broader UAE market access, free zone regulations may differ from federal MOHAP requirements, some free zones accept international certifications more readily. Strategy: Manufacturers targeting both free zone and mainland UAE markets should pursue MOHAP registration; those focused solely on specific free zone facilities may have streamlined pathways.

Question 7

How often is UAE medical device regulatory news updated and how can I stay informed?

Accepted Answer

MOHAP and the GCC regulatory authorities regularly publish updates to registration procedures, technical regulations, and safety alerts. Changes may affect MDMA requirements, GCC-DR harmonization, and local agent responsibilities. Our platform aggregates daily updates from 7 premium commercial sources including RAPS, Emergo by UL, Pacific Bridge Medical, and Citeline. We recommend checking this page regularly and working closely with your UAE Local Agent to monitor MOHAP and GCC announcements.

Question 8

What commercial sources does this platform use for UAE news?

Accepted Answer

We aggregate UAE regulatory intelligence from 7 premium sources: RAPS (Regulatory Affairs Professionals Society), Emergo by UL, Citeline MedTech Insight, Pacific Bridge Medical, Asia Actual, Pure Global's proprietary research, and Qualtechs. These sources provide expert analysis, real-time updates, and strategic insights beyond basic MOHAP announcements, helping you navigate MDMA registration, GCC-DR compliance, local agent selection, and regional Gulf market access strategies.

UAE MOHAP Medical Device News 2025: Registration & Regulatory Updates | Pure Global

Frequently Asked Questions About MOHAP News